918博天堂(中国)百度百科

Metastatic castration-resistant prostate cancer
Single Agent

Phase I

HER2-expressing or -mutated solid tumors
Single Agent

Phase I

Advanced breast cancer
Single Agent

Phase I

Advanced breast cancer
Combination Therapy (dalpiciclib)

Phase I

Multiple myeloma and non-Hodgkin's lymphoma (NHL)
Single Agent/Combination Therapy (dexamethasone-containing regimen)

Phase I

Advanced solid tumors
Combination Therapy (adebrelimab/aumolertinib)

Phase II

ER-positive unresectable or metastatic breast cancer
Combination Therapy (SHR-A1811, HRS-8080)

Phase II

Advanced solid tumors
Combination Therapy (SHR-9839 or SHR-A1921 or aumolertinib or chemotherapy)

Phase II

Advanced solid tumors
Combination Therapy (bevacizumab or SHR-8068)

Phase II

Advanced or metastatic solid tumors
Single Agent

Phase I

Advanced solid tumors
Single Agent

Phase I
Japan and Korea

Advanced solid tumors
Combination Therapy (SHR-A1921 or bevacizumab or abiraterone acetate tablets (I) and prednisone/prednisolone (AA-P))

Phase II

Advanced solid tumors
Combination Therapy (antineoplastic therapy)

Phase II

Advanced solid tumors
Single Agent

Phase I

Advanced solid tumors
Single Agent

Phase II
US

Advanced solid tumors
Combination Therapy (adebrelimab ± SHR-8068 ± standard therapy)

Phase II

Locally advanced or metastatic esophageal cancer
Combination Therapy (adebrelimab ± antineoplastic therapy)

Phase II

Advanced solid tumors
Single Agent

Phase I

Non-muscle invasive bladder cancer
Combination Therapy (BCG bladder perfusion)

Phase II

Advanced solid tumors
Combination Therapy (camrelizumab+famitinib)

Phase II

Advanced solid tumors
Combination Therapy (adebrelimab)

Phase II

Advanced solid tumors
Single Agent

Phase I

Relapsed and refractory peripheral T-cell lymphoma
Single Agent

Phase III

Mature lymphocytic tumors
Combination Therapy (CHOP/CHOEP or CD20 mAb)

Phase II

Relapsed and refractory follicular lymphoma
Single Agent

Phase II

Refractory/relapsed mature lymphoma
Single Agent

Phase I

Platinum-sensitive recurrent epithelial ovarian cancer
Single Agent or Combination Therapy with carboplatin

Phase III

Platinum-resistant recurrent epithelial ovarian cancer
Single Agent

Phase III

Advanced solid tumors
Combination Therapy (adebrelimab, or in combination with carboplatin/ cisplatin, or adebrelimab and carboplatin/cisplatin, or bevacizumab)

Phase II

Advanced solid tumors
Single Agent

Phase II
US, Australia

Advanced solid tumors
Combination Therapy (antineoplastic therapy)

Phase II

Advanced solid tumors
Combination Therapy (HRS-1167 or bevacizumab or abiraterone acetate tablets (I) and prednisone/prednisolone (AA-P))

Phase II

Advanced solid tumors
Combination Therapy (adebrelimab+SHR-8068+aumolertinib/bevacizumab/carboplatin/cisplatin)

Phase II

Advanced solid tumors
Combination Therapy (SHR-9839 or SHR-A2009 or aumolertinib or chemotherapy

Phase II

Advanced solid tumors
Single Agent

Phase I

Advanced or metastatic gastric cancer (GC) or gastroesophageal junction cancer
Combination Therapy (chemotherapy)

Phase III

Advanced solid tumors
Combination Therapy (bevacizumab)

Phase II

Perioperative rectal cancer
Combination Therapy (radiotherapy/chemotherapy)

Phase II

Recurrent or advanced non-small cell lung cancer with EGFR mutation
Combination Therapy (almonertinib)

Phase II

Inoperable stage III non-small cell lung cancer
Combination Therapy (radiotherapy/chemotherapy)

Phase II

HER2-positive advanced gastric cancer (GC) or adenocarcinoma of the gastroesophageal junction
Combination Therapy (SHR-A1811)

Phase II

Advanced solid tumors
Single Agent

Phase I

Recurrent or metastatic nasopharyngeal carcinoma
Single Agent

Phase I

Advanced solid tumors
Single Agent

Phase I
Australia

HER2-positive metastatic breast cancer
Single Agent

Phase III

HER2-low recurrent/metastatic breast cancer
Single Agent

Phase III

Adjuvant therapy for HER2-positive breast cancer
Single Agent

Phase III

HER2-positive recurrent or metastatic breast cancer
Single Agent or Combination Therapy (pertuzumab)

Phase III

HER2-positive advanced gastric cancer or gastroesophageal junction adenocarcinoma with failed first-line anti-HER2 therapy
Single Agent

Phase III

HER2-positive advanced colorectal cancer with failed treatment with oxaliplatin, fluorouracil, and irinotecan
Single Agent

Phase III

1st-line treatment for HER2-mutated advanced or metastatic non-small cell lung cancer
Single Agent

Phase III

HER2-positive unresectable or metastatic breast cancer
Combination Therapy (pyrotinib/pertuzumab/adebrelimab/albumin-bound paclitaxel)

Phase II

Advanced solid tumors with HER2 expression
Combination Therapy (fuzuloparib)

Phase II

Advanced non-small cell lung cancer with HER2 mutation, amplification, or overexpression
Combination Therapy (pyrotinib/adebrelimab)

Phase II

HER2 mutated/amplified/high-expression non-small cell lung cancer
Single Agent

Phase II

HER2-positive advanced gastric cancer (GC) or adenocarcinoma of the gastroesophageal junction
Combination Therapy (SHR-1701)

Phase II

HER2-low metastatic or unresectable breast cancer
Combination Therapy (capecitabine)

Phase II

HER2-low advanced breast cancer
Combination Therapy (dalpiciclib, fulvestrant, bevacizumab or letrozole/anastrozole)

Phase II

HER2-positive advanced solid tumors
Combination Therapy (pyrotinib or bevacizumab, capecitabine and oxaliplatin or other standard treatment)

Phase II

HER2-expressing gynecological malignancies
Single Agent

Phase II

ER-positive unresectable or metastatic breast cancer
Combination Therapy (HRS-8080, SHR-A2009)

Phase II

HER2-aberrant advanced solid tumors
Combination Therapy (adebrelimab ± SHR-8068)

Phase II

HER2-expressing advanced gastric or gastroesophageal junction adenocarcinoma
Combination Therapy (adebrelimab+chemotherapy)

Phase II

Locally advanced unresectable or recurrent metastatic biliary tract cancer with ER2 expression/amplification
Single Agent

Phase II

Advanced solid tumors
Single Agent

Phase I

Gastric cancer or adenocarcinoma of the gastroesophageal junction and colorectal cancer
Single Agent

Phase I

Advanced solid tumors
Single Agent

Phase I
US, Australia, Asia Pacific (including China)

Advanced solid tumors
Combination Therapy (adebrelimab)

Phase III

Advanced pancreatic cancer
Single Agent

Phase I

Advanced solid tumors
Single Agent

Phase I
US, Australia, China

Recurrent metastatic cervical cancer
Combination Therapy (camrelizumab)

NDA/BLA Filed

1st-line advanced cervical cancer
Combination Therapy (camrelizumab)

Phase III

1st-line PD-L1 positive non-small cell lung cancer
Combination Therapy (camrelizumab)

Phase III

Advanced solid tumors
Combination Therapy (camrelizumab+albumin-bound paclitaxel)

Phase II

Advanced solid tumors
Combination Therapy (camrelizumab+SHR-1802)

Phase II

Prevention of chemotherapy-induced nausea and vomiting
Single Agent

NDA/BLA Filed

Prevention of nausea and vomiting caused by antineoplastic drugs with moderate risk of vomiting
Single Agent (FDC)

Phase III

Advanced gastric adenocarcinoma or gastroesophageal junction adenocarcinoma progressed or relapsed after at least 2Ls of systematic chemotherapy
Single Agent

Marketed

Advanced hepatocellular carcinoma failed or intolerable after at least first-line systemic therapy
Single Agent

Marketed

1st-line unresectable or metastatic hepatocellular carcinoma
Combination Therapy (camrelizumab)

Marketed

Metastatic HER2-negative breast cancer with BRCA1/2 mutation
Combination Therapy (fuzuloparib)

NDA/BLA Filed

1st-line unresectable or metastatic hepatocellular carcinoma
Combination Therapy (camrelizumab)

NDA/BLA Filed
US, Europe, and Asia Pacific (including China)

Adjuvant therapy for hepatocellular carcinoma (HCC) patients with high risk of recurrence after radical surgery or ablation
Combination Therapy (camrelizumab)

Phase III

Unresectable HCC
Combination Therapy (TACE+camrelizumab)

Phase III

Relapsed or metastatic advanced HER2-positive breast cancer patients without previous HER2 treatment
Combination Therapy (trastuzumab+docetaxel)

Marketed

Relapsed or metastatic HER2-positive breast cancer with previous trastuzumab treatment
Combination Therapy (capecitabine)

Marketed

Neoadjuvant treatment for early or locally advanced HER2-positive breast cancer
Combination Therapy (trastuzumab+docetaxel)

Marketed

Extended adjuvant therapy for HER2-positive breast cancer
Single Agent

Phase III

Advanced non-squamous non-small cell lung cancer with HER2 mutation
Single Agent

Phase III
US, Europe, and Asia Pacific (including China)

Advanced non-small cell lung cancer with HER2 mutation, amplification, or overexpression
Combination Therapy (SHR-A1811)

Phase II

Advanced HER2-positive unresectable or metastatic breast cancer
Combination Therapy (SHR-A1811)

Phase II

Advanced HER2-positive solid tumors
Combination Therapy (SHR-A1811 or bevacizumab, capecitabine and oxaliplatin, or other standard treatment)

Phase II

Relapsed and refractory classical Hodgkin lymphoma after at least two systematic therapies
Single Agent

Marketed

Advanced hepatocellular carcinoma after sorafenib and/or oxaliplatin-containing chemotherapy treatments
Single Agent

Marketed

Unresectable locally advanced or metastatic EGFR-mut negative ALK-negative NSCLC
Combination Therapy (pemetrexed+carboplatin)

Marketed

Locally advanced or metastatic esophageal adenocarcinoma progressed after or intolerable to 1st-line treatment
Single Agent

Marketed

Advanced nasopharyngeal carcinoma progressed after or intolerable to 2nd-line+ chemotherapy
Single Agent

Marketed

1st-line locally relapsed or metastatic nasopharyngeal carcinoma
Combination Therapy (cisplatin+gemcitabine)

Marketed

1st-line unresectable locally advanced/relapsed or metastatic esophageal squamous cell carcinoma
Combination Therapy (cisplatin+paclitaxel)

Marketed

1st-line locally advanced/metastatic squamous non-small cell lung cancer
Combination Therapy (carboplatin+paclitaxel)

Marketed

1st-line unresectable or metastatic hepatocellular carcinoma
Combination Therapy (apatinib)

Marketed

Recurrent metastatic cervical cancer
Combination Therapy (famitinib)

NDA/BLA Filed

1st-line advanced hepatocellular carcinoma
Combination Therapy (apatinib)

NDA/BLA Filed
US, Europe, and Asia Pacific (including China)

Relapsed and refractory classical Hodgkin lymphoma
Single Agent

Phase III

Adjuvant therapy for hepatocellular carcinoma (HCC) patients with high risk of recurrence after radical surgery or ablation
Combination Therapy (apatinib)

Phase III

Unresectable HCC
Combination Therapy (TACE+apatinib)

Phase III

Unresectable locally advanced esophageal cancer
Combination Therapy (radiotherapy+chemotherapy)

Phase III

1st-line advanced cervical cancer
Combination Therapy (famitinib)

Phase III

1st-line PD-L1 positive non-small cell lung cancer
Combination Therapy (famitinib)

Phase III

Advanced solid tumors
Combination Therapy (famitinib+albumin-bound paclitaxel)

Phase II

Advanced solid tumors
Combination Therapy (famitinib+SHR-1802)

Phase II

1st-line metastatic pancreatic cancer
Combination Therapy (surufatinib+albumin-bound paclitaxel+gemcitabine)

Phase II

Maintenance therapy for advanced ovarian cancer after platinum-containing therapy
Single Agent

Marketed

Recurrent platinum-sensitive gBRCA-mut ovarian carcinoma, fallopian tube carcinoma, or primary peritoneal carcinoma after 2nd-line+ chemotherapy
Single Agent

Marketed

Maintenance therapy for platinum-sensitive recurrent epithelial ovarian carcinoma, fallopian tube carcinoma, or primary peritoneal carcinoma after platinum-containing chemotherapy
Single Agent

Marketed

Metastatic HER2-negative breast cancer with BRCA1/2 mutation
Single Agent/Combination Therapy (apatinib)

NDA/BLA Filed

Metastatic castration-resistant prostate cancer
Combination Therapy (abiraterone)

Phase III
US, Europe, and Asia Pacific (including China)

Advanced solid tumors with HER2 expression
Combination Therapy (SHR-A1811)

Phase II

Relapsed or metastatic HR-positive HER2-negative breast cancer progressed after endocrine therapy
Combination Therapy (fulvestrant)

Marketed

Locally advanced or metastatic HR-positive HER2-negative breast cancer
Combination Therapy (aromatase inhibitor)

Marketed

Adjuvant therapy for HR-positive, HER2-negative breast cancer
Combination Therapy (endocrine therapy)

Phase III

Advanced HER2-low breast cancer
Combination Therapy (SHR-A1811, fulvestrant, bevacizumab, or letrozole/anastrozole)

Phase II

ER-positive, HER2-negative unresectable or metastatic breast cancer
Combination Therapy (HRS-8080)

Phase II

Advanced breast cancer
Combination Therapy (HRS-8807)

Phase I

Breast Cancer
Combination Therapy (HRS-1358)

Phase I

Diabetes
Single Agent

Phase I

Lipoprotein disorders
Single Agent

Phase I

Hyperlipidemia
Single Agent

Phase I

Acute ischemic stroke
Single Agent

Phase I

Type 2 diabetes mellitus
Single Agent

Phase II

Overweight or obesity
Single Agent

Phase II

Diabetic kidney disease
Single Agent

Phase II

Prevention or treatment of arteriovenous thrombosis
Single Agent

Phase II

Hyperlipidemia and homozygous familial hypercholesterolemia
Single Agent

Phase II

Cardiac hypertrophy
Single Agent

Phase II

Type 2 diabetes mellitus
Single Agent

Phase III

Type 2 diabetes mellitus
Single Agent (FDC)

Phase III

Overweight or obesity
Single Agent

Phase III

Type 2 diabetes mellitus
Single Agent

Phase II

Obesity with heart failure
Single Agent

Phase II

Weight management and type 2 diabetes mellitus
Single Agent (tablet)

Phase I

Type 2 diabetes mellitus
Single Agent (FDC)

NDA/BLA Filed

Type 2 diabetes mellitus
Single Agent (FDC)

NDA/BLA Filed

Primary hypercholesterolemia and mixed hyperlipidemia
Single Agent

NDA/BLA Filed

Primary hypercholesterolemia and mixed hyperlipidemia with poor lipid control
Combination Therapy (lipid-lowering drugs)

NDA/BLA Filed

Heterozygous familial hypercholesterolemia
Single Agent

NDA/BLA Filed

Type 2 diabetes mellitus
Combination Therapy (metformin+retagliptin)

Marketed

Improve glycemic control in adults with type 2 diabetes mellitus
Single Agent

Marketed

Chronic kidney disease
Single Agent

Phase II

Type 2 diabetes mellitus
Combination Therapy (metformin+henagliflozin)

Marketed

Type 2 diabetes mellitus
Single Agent/Combination Therapy (metformin)

Marketed

Type 2 diabetes mellitus
Single Agent (FDC)

Marketed

Healthy volunteers
Single Agent

Phase I
Australia

Inflammatory bowel disease includes ulcerative colitis and Crohn's disease
Single Agent

Phase I

Chronic Obstructive Pulmonary Disease (COPD)
Single Agent

Phase I

Rheumatoid arthritis
Single Agent

Phase I

Systematic lupus erythematosis
Single Agent

Phase I

Prevention treatment for graft rejection after organ transplantation
Single Agent

Phase I

Asthma
Single Agent

Phase II

Chronic rhinosinusitis with nasal polyp (CRSwNP)
Single Agent

Phase II

Chronic obstructive pulmonary disease
Single Agent

Phase I

Healthy volunteers
Single Agent

Phase I
Australia

IgA nephropathy
Single Agent

Phase II

IgA nephropathy
Single Agent

Phase II

Paroxysmal nocturnal hemoglobinuria
Single Agent

Phase II

Complement-mediated primary/secondary glomerular disease; Complement-mediated hemolytic anemia
Single Agent (capsule)

Phase I

Primary gout with hyperuricemia
Single Agent

Phase III

Gout patient with Hyperuricemia
Combination Therapy (febuxostat)

Phase II

Atopic dermatitis
Single Agent

Phase III

Moderate-to-severe chronic sinusitis with nasal polyps
Single Agent

Phase II

Healthy volunteers
Single Agent

Phase I
China, Australia

Eosinophilic granulomatosis with polyangiitis
Single Agent

Phase III

Severe eosinophilic asthma
Single Agent

Phase II

IgA nephropathy
Single Agent

Phase III

Autoimmune hepatitis
Single Agent

Phase II

Gout patient with Hyperuricemia
Single Agent

Phase III

Ankylosing spondylitis
Single Agent

NDA/BLA Filed

Moderate-to-severe active rheumatoid arthritis
Single Agent

NDA/BLA Filed

Moderate-to-severe atopic dermatitis
Single Agent

NDA/BLA Filed

Psoriatic arthritis
Single Agent

Phase III

Active radiologically negative mid-axis spondyloarthritis
Single Agent

Phase III

Alopecia
Single Agent

Phase III

Mild-to-moderate atopic dermatitis
Single Agent (ointment)

Phase III

Ulcerative colitis
Single Agent

Phase III
US, Europe, China

Moderate-to-severe atopic dermatitis
Single Agent

Phase III
Canada, China

Vitiligo
Single Agent (alkaline gel)

Phase I

Graft-versus-host disease (GVHD)
Single Agent (oral solution)

Phase I

Adults with moderate to severe plaque psoriasis who are receiving systemic therapy or phototherapy
Single Agent

Marketed

Active ankylosing spondylitis in adults
Single Agent

NDA/BLA Filed

Moderate-to-severe chronic plaque psoriasis in children and adolescents
Single Agent

Phase III

Psoriatic arthritis
Single Agent

Phase II

Adult chronic primary immune thrombocytopenia after glucocortocoids or immunoglobulin treatment
Single Agent

Marketed

Severe aplastic anemia after immunosuppressive therapy
Single Agent

Marketed

Chemotherapy-induced thrombocytopenia
Single Agent

Phase III
US, Australia, Europe, and China

Primary treatment of severe aplastic anemia
Combination Therapy (standard immunosuppressive therapy)

Phase III

Children with immune thrombocytopenia (ITP)
Single Agent

Phase III

Chronic liver disease with thrombocytopenia with invasive procedures or surgeries
Single Agent

Phase III

Primary treatment of non-severe aplastic anemia
Combination therapy (cyclosporine)

Phase II

Post-operative analgesia for hemorrhoidectomy
Single Agent

Phase III

Adductor canal block
Single Agent

Phase II

Intercostal nerve block
Single Agent

Phase II

Post-operative analgesia for abdominal surgeries
Single Agent

Marketed

Moderate to severe pain after orthopedic surgery
Single Agent

NDA/BLA Filed

Osteoarthritis-related pain
Single Agent

Marketed

Colonoscopy sedation, bronchoscopy sedation, and general anethesia
Single Agent

Marketed

ICU sedation with mechanical ventilation
Single Agent

Phase II

Pre-operative analgesia/anxiolytic for pediatric patients from age 2-6
Single Agent

Marketed

Pre-operative analgesia/anxiolytic for adult patients
Single Agent

Marketed

Chronic hepatitis B
Single Agent

Phase II

Candidemia or invasive candidiasis
Single Agent

Phase II

Chronic hepatitis B
Single Agent

Phase II

Complicated urinary tract infection
Single Agent

Phase III

Pulmonary infection
Single Agent

Phase I

Severe vulvovaginal candidiasis
Single Agent

Marketed

Recurrent vulvovaginal candidiasis
Single Agent

Phase III

Non-cystic fibrosis bronchiectasis
Single Agent

Phase I

Maintenance treatment for bronchial asthma
Single Agent

Phase I

Idiopathic pulmonary fibrosis
Single Agent

Phase I

Autosomal dominant polycystic kidney disease
Single Agent (tablet)

Phase I

Fluid retention due to heart failure
Single Agent (injectable)

Phase I

Magnetic resonance imaging (MRI) of all parts of the body detects and shows abnormal vascular lesions
Single Agent

Phase I

Chronic kidney disease
Single Agent

Phase II

Osteoporosis
Single Agent

Phase II

Alzheimer's disease
Single Agent

Phase II

Alzheimer's disease
Single Agent

Phase I
Australia

Severe cerebral edema after massive ischemic stroke
Single Agent

Phase II

Chronic cough
Single Agent

Phase II

Secondary hyperparathyroidism in patients with chronic kidney disease on maintenance hemodialysis
Single Agent

Phase III

Slow down progression of myopia for pediatric patients
Single Agent

Phase III

Uterine fibroids with heavy menstrual bleeding
Single Agent

Phase III

Controlled ovarian hyperstimulation in assisted reproductive technology
Single Agent

Phase III

Endometriosis
Single Agent

Phase II

Dry eye syndrome associated with meibomian gland dysfunction
Single Agent

NDA/BLA Filed

Dry eye syndrome (keratoconjunctivitis sicca)
Single Agent

NDA/BLA Filed